
SOPH Earnings
Sophia Genetics SA
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Sophia Genetics SA(SOPH) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Sophia Genetics SA earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-05 | Pre-Market | - | 0.33 | - | 17.49M | 18.32M | +4.77 | +3.64 | -3.64 |
FY2025Q1 | 2025-05-06 | Pre-Market | -0.21 | -0.26 | -23.81 | 16.75M | 17.78M | +6.11 | -4.46 | -6.72 |
FY2024Q4 | 2025-03-04 | Pre-Market | -0.24 | -0.23 | +4.17 | 17.71M | 17.73M | +0.10 | -13.17 | -10.08 |
FY2024Q3 | 2024-11-05 | Pre-Market | -0.24 | -0.28 | -16.67 | 16.06M | 15.85M | -1.29 | - | +1.07 |
FY2024Q2 | 2024-08-06 | - | -0.28 | -0.23 | +17.86 | 17.45M | 15.81M | -9.39 | -2.17 | -23.13 |
FY2024Q1 | 2024-05-07 | - | -0.25 | -0.21 | +16.00 | 16.45M | 15.78M | -4.09 | -1.58 | -9.31 |
FY2023Q4 | 2024-03-05 | - | -0.25 | -0.37 | -48.00 | 17.33M | 17.05M | -1.60 | -0.36 | -13.70 |
FY2023Q3 | 2023-11-07 | - | -0.32 | -0.21 | +34.38 | 15.45M | 16.30M | +5.52 | +1.30 | -16.58 |
FY2023Q2 | 2023-08-08 | - | -0.29 | -0.33 | -13.79 | 15.24M | 15.05M | -1.19 | +5.65 | -10.71 |
- | 2023-05-09 | - | -0.28 | -0.31 | -10.71 | - | - | - | +1.89 | -6.30 |
SOPH Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Sophia Genetics SA reported performance for FY2025Q2, announced on 2025-08-05. The company achieved an EPS of 0.33, compared to analyst estimates of by % . Revenue for the quarter reached 18.32M compared to expectations of 17.49M by 4.77% .
The stock price reacted with a 3.64% one-day change and a -3.64% five-day change following the earnings release. These movements reflect market reaction in Sophia Genetics SA growth trajectory and strategic initiatives.
SOPH Earnings Forecast
Looking ahead, Sophia Genetics SA(SOPH) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 18.30M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.05%, while EPS estimates have been Revise Downward by -1.27%. For the upcoming , revenue estimates have been adjusted Go Down by -5.49% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Sophia Genetics SA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between SOPH's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+0.05%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Downward

-1.27%
In Past 3 Month
Stock Price
Go Down

-5.49%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:74.20M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price3.01
SOPH Revenue and EPS Performance: A Historical Perspective
Sophia Genetics SA revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-05,Pre-Market):
EPS: 0.33 (Actual) vs. (Estimate) (%)
Revenue: 18.32M (Actual) vs. 17.49M (Estimate) (4.77%)
Price Reaction: 3.64%(1-Day), -3.64%(5-Day)
FY2025Q1 (2025-05-06,Pre-Market):
EPS: -0.26 (Actual) vs.-0.21 (Estimate) (-23.81%)
Revenue: 17.78M (Actual) vs. 16.75M (Estimate) (6.11%)
Price Reaction: -4.46%(1-Day), -6.72%(5-Day)
FY2024Q4 (2025-03-04,Pre-Market):
EPS: -0.23 (Actual) vs.-0.24 (Estimate) (4.17%)
Revenue: 17.73M (Actual) vs. 17.71M (Estimate) (0.10%)
Price Reaction: -13.17%(1-Day), -10.08%(5-Day)
Earnings Reaction
The chart below shows how SOPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SOPH sees a +3.15% change in stock price 10 days leading up to the earnings, and a -8.74% change 10 days following the report. On the earnings day itself, the stock moves by -0.93%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -7.95% on the day following the earnings release and then changed by -11.99% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Summary
Positive
2025-08-05
The earnings call highlights strong U.S. market growth, improved gross margins, and significant partnership expansion with AstraZeneca, which is the largest in the company's history. Despite an increase in operating loss, the company's strategic focus on new applications, customer growth, and cost management reflect a positive outlook. The Q&A section reinforces this sentiment with optimistic guidance on product adoption and contract value increases. Although management was conservative about disclosing specific contract sizes, the overall narrative suggests positive momentum, warranting a 'Positive' sentiment rating.
Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Summary
Neutral
2025-05-09
The earnings call presents mixed signals: positive revenue growth, improved EBITDA loss, and strong gross margins, but concerns over churn and competitive pressures. The Q&A highlights effective implementation and partnerships, yet lacks clarity on sustainable margins. No share buyback program and a cautious revenue guidance contribute to a neutral outlook.
Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Summary
Negative
2025-03-05
The earnings call reveals competitive pressures and customer churn, leading to revenue growth below expectations. Exchange rate volatility and economic uncertainties further dampen the outlook. Although there are improvements in adjusted margins and operating losses, cash burn increased, and there's no shareholder return plan. Management's vague responses in the Q&A add to concerns. Overall, the negative factors outweigh the positives, suggesting a likely stock price decline in the short term.
Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Summary
Negative
2025-03-04
The earnings call highlights some positive aspects like improved operating losses and adjusted EBITDA, but concerns arise from declining gross margins, increased cash burn, and unclear management responses. The BioPharma sector's revenue decline and uncertainties around ASP and customer volume metrics further contribute to a negative outlook. The Q&A reveals optimism in certain areas but lacks concrete guidance, which could lead to market skepticism. Overall, the mixed signals and financial challenges suggest a negative sentiment.
Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Summary
Neutral
2025-03-04
The earnings call highlights both positive and negative aspects. Positive elements include improved adjusted gross margins, operating loss, and new customer acquisition. However, concerns arise from declining gross margins, increased cash burn, and unclear guidance on biopharma funding impacts. The Q&A revealed management's evasiveness on certain metrics, adding uncertainty. Overall, these mixed signals suggest a neutral stock price movement.
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Summary
Neutral
2024-11-05
The earnings call summary presents mixed signals: a decline in total revenue and gross profit, but improvements in cash burn and operating loss. The reaffirmed revenue guidance and adjusted gross margin are positive, but biopharma revenue weakness and pricing pressures in Europe are concerns. The Q&A session reveals management's confidence in future growth and stabilization, but lacks specific guidance, particularly for 2025. The improved cash position and customer growth are positives, yet the market's response may be cautious due to the revenue decline and biopharma challenges, resulting in a neutral sentiment.
SOPHiA GENETICS SA (SOPH) Q2 2024 Earnings Call Summary
Neutral
2024-08-06
The earnings call presents a mixed outlook. Financial performance showed modest growth, but revenue outlook was revised down, signaling challenges in BioPharma and EMEA. The Q&A highlighted uncertainties in signing deals and competitive pricing pressures. However, improvements in operating losses and cash burn, alongside strong pipeline growth and optimistic guidance for future profitability, balance these concerns. The market reaction is likely to be neutral, reflecting both the positive steps towards profitability and the negative impact of revised revenue guidance and market challenges.
People Also Watch

GROY
Gold Royalty Corp
3.100
USD
-4.02%

NUTX
Nutex Health Inc
89.630
USD
+1.94%

AZ
A2Z Cust2Mate Solutions Corp
9.820
USD
+3.92%

GAUZ
Gauzy Ltd
6.600
USD
+5.77%

ESSA
ESSA Bancorp Inc
20.690
USD
+2.47%

CIO
City Office REIT Inc
6.940
USD
-0.14%

HWBK
Hawthorn Bancshares Inc
29.260
USD
+1.60%

SJT
San Juan Basin Royalty Trust
5.820
USD
-0.17%

HURA
TuHURA Biosciences Inc
3.050
USD
+32.61%

HMST
HomeStreet Inc
12.910
USD
+1.97%
FAQ

What were the key highlights of SOPH’s latest earnings report for FY2025Q2?
SOPH reported its FY2025Q2 earnings on 2025-08-05, showcasing a revenue of 18.32M against an estimate of 17.49M, resulting in a 4.77% surprise. The EPS was 0.33, surpassing the expected 0 by 0% . The stock experienced a 3.64% price change on the earnings day and a -3.64% change over the next five days, reflecting market reactions to the results.

How did SOPH’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for SOPH for 2025/Q3?

How does SOPH’s stock price correlate with earnings forecast revisions?

What should investors expect from SOPH’s next earnings report?
